Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.
The identification of five dopamine receptor subtypes has given the dopamine hypothesis of schizophrenia new life. The D4 receptor is particularly intriguing because it binds clozapine with high affinity. Putative D4 receptors were labeled in postmortem human brain by subtracting the binding of a saturating concentration of 3H-raclopride (6 nM, which labels D2 and D3 receptors) from that labeled by a saturating concentration of [3H]YM 09151-2 (1-1.3 nM, which labels D2, D3, and D4 receptors). In the control brain, putative D4 receptors show a homogenous distribution in striatum and nucleus accumbens. This is also true in schizophrenic brains, although the levels are significantly higher (twofold). These data are inconsistent with mRNA studies that have shown negligible amounts in striatum and accumbens, with modest amounts reported in most of cerebral cortex. These findings suggest that the putative D4 receptors are not synthesized in this region, but are presynaptically localized on striatal afferent terminals. Our findings confirm and extend the report of Seeman et al. (1993). Extension of these findings into the nucleus accumbens is important because of its extensive connections to the limbic system while the putamen is exclusively "motor" striatum.
Murray
A M
AM
National Institute of Mental Health, Clinical Brain Disorders Branch, St. Elizabeths Hospital, Washington, D.C. 20032.
Hyde
T M
TM
Knable
M B
MB
Herman
M M
MM
Bigelow
L B
LB
Carter
J M
JM
Weinberger
D R
DR
Kleinman
J E
JE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides / Q000378:metabolism; D003342:Corpus Striatum / Q000737:chemistry*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy / Q000378:metabolism; D008875:Middle Aged; D009714:Nucleus Accumbens / Q000737:chemistry / Q000473:pathology; D020891:Raclopride; D011869:Radioligand Assay; D011954:Receptors, Dopamine / Q000032:analysis* / Q000378:metabolism; D017448:Receptors, Dopamine D2; D050638:Receptors, Dopamine D4; D012457:Salicylamides / Q000378:metabolism; D012559:Schizophrenia / Q000378:metabolism* / Q000473:pathology; D013405:Suicide; D015854:Up-Regulation
D014150:Antipsychotic Agents; D001549:Benzamides; C493599:DRD4 protein, human; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D050638:Receptors, Dopamine D4; D020891:Raclopride; C030265:nemonapride